Skip to main content
. Author manuscript; available in PMC: 2020 Aug 6.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2019 Jul;69(1):61–67. doi: 10.1097/MPG.0000000000002362

FIGURE 1.

FIGURE 1.

Ustekinumab remission rates at 1 year in biologic-exposed (n = 42) versus biologic-naïve (n = 10) Crohn disease and ulcerative colitis/inflammatory bowel disease-unspecified pediatric patients. Note overlap in patients achieving any of the 3 remission outcomes. TNF = tumor necrosis factor.